AOD-9604 is a modified fragment of human growth hormone, specifically amino acids 176 through 191 of the GH molecule. This C-terminal fragment was isolated because research suggested it retained the fat-metabolizing properties of full GH without its growth-promoting or diabetogenic effects.
The proposed mechanism involves stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation). Unlike full-length growth hormone, AOD-9604 does not appear to affect blood sugar levels or stimulate IGF-1 production in preclinical models.
AOD-9604 was originally developed by a pharmaceutical company and progressed through clinical trials for obesity treatment. Although it did not receive FDA approval as a drug, the research data generated during these trials contributes to the scientific understanding of the compound.
The peptide is available in various dosages as a lyophilized powder for research use. It is reconstituted with bacteriostatic water and typically studied via subcutaneous administration in preclinical protocols.
AOD-9604 is sold strictly for laboratory research. It is not approved for human therapeutic use in any jurisdiction.
Disclaimer: This article is for educational purposes only. All peptides are sold for laboratory research use only. Not for human consumption.